BSE Live
Nov 07, 16:01Prev. Close
6886.30
Open Price
6836.05
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 07, 15:58Prev. Close
6883.50
Open Price
6874.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
6656.50 (419)
| Profit & Loss account of Divis Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 3,099.24 | 2,525.46 | 2,139.31 | 1,857.19 | 1,322.71 | |
| Less: Excise/Sevice Tax/Other Levies | 26.94 | 18.29 | 15.36 | 17.69 | 14.05 | |
| Revenue From Operations [Net] | 3,072.30 | 2,507.17 | 2,123.95 | 1,839.49 | 1,308.66 | |
| Total Operating Revenues | 3,084.01 | 2,513.97 | 2,128.89 | 1,844.93 | 1,314.87 | |
| Other Income | 42.84 | 83.90 | 48.51 | 65.76 | 29.23 | |
| Total Revenue | 3,126.85 | 2,597.87 | 2,177.40 | 1,910.69 | 1,344.09 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 1,446.27 | 1,031.89 | 897.90 | 771.77 | 486.68 | |
| Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.09 | 0.10 | 0.00 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -230.83 | -113.75 | -100.33 | -10.66 | 34.52 | |
| Employee Benefit Expenses | 283.15 | 225.43 | 191.20 | 145.16 | 112.06 | |
| Finance Costs | 1.86 | 2.06 | 1.78 | 3.74 | 1.52 | |
| Depreciation And Amortisation Expenses | 135.85 | 92.06 | 76.90 | 62.03 | 53.35 | |
| Other Expenses | 423.37 | 351.54 | 318.28 | 243.69 | 176.92 | |
| Total Expenses | 2,059.67 | 1,589.23 | 1,385.82 | 1,215.83 | 865.05 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 1,067.18 | 1,008.64 | 791.58 | 694.86 | 479.05 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 1,067.18 | 1,008.64 | 791.58 | 694.86 | 479.05 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 216.20 | 206.15 | 153.00 | 132.75 | 39.20 | |
| Less: MAT Credit Entitlement | 7.35 | 23.67 | -7.90 | -3.68 | -1.28 | |
| Deferred Tax | 10.78 | 35.12 | 19.26 | 12.38 | 3.01 | |
| Tax For Earlier Years | 0.49 | -0.68 | 0.00 | 0.08 | 0.00 | |
| Total Tax Expenses | 220.12 | 216.92 | 180.16 | 148.89 | 43.48 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 847.06 | 791.72 | 611.42 | 545.97 | 435.57 | |
| Profit/Loss From Continuing Operations | 847.06 | 791.72 | 611.42 | 545.97 | 435.57 | |
| Profit/Loss For The Period | 847.06 | 791.72 | 611.42 | 545.97 | 435.57 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 63.82 | 59.65 | 46.06 | 41.15 | 32.90 | |
| Diluted EPS (Rs.) | 63.82 | 59.65 | 46.06 | 41.15 | 32.88 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 722.51 | 488.17 | 370.29 | 303.20 | 161.88 | |
| Indigenous Raw Materials | 723.77 | 543.73 | 527.61 | 468.57 | 324.80 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 2.53 | 0.48 | 2.25 | 1.02 | 0.59 | |
| Indigenous Stores And Spares | 13.52 | 13.25 | 10.32 | 15.63 | 12.64 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 265.47 | 265.47 | 199.10 | 172.55 | 132.60 | |
| Tax On Dividend | 54.04 | 45.12 | 33.84 | 27.99 | 21.51 | |
| Equity Dividend Rate (%) | 1,000.00 | 1,000.00 | 750.00 | 650.00 | 500.00 |
10.09.2025
Reduce Divis Laboratories; target of Rs 5400: Geojit Financial Services
07.08.2025
Accumulate Divis Laboratories; target of Rs 6550: Prabhudas Lilladher
07.08.2025
Divis Labs Standalone June 2025 Net Sales at Rs 2,357.00 crore, up 14.25% Y-o-Y
23.05.2025
Accumulate Divis Laboratories; target of Rs 7518: Deven Choksey
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill